longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Moleculin Biotech

MBRX

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -0.31, within the reasonable range, cheaper than 38.87% of the time in the past 3 years, and the industry ranks 114/602, the industry Median -2.44.

-0.312xP/E
$0.52Stock price
$-1.67Earnings per share
-0.312xP/E
Stock price$0.52Earnings per share$-1.67

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-0.38x
Typical range
-0.61x–-0.24x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-57.62x148.77%$186.69B
MRNAUSModerna
-21.91x15.47%$69.04B
CSLLYUSCSL Limited
-23.70x--$61.13B
NTRAUSNatera
-277.76x10.38%$53.43B
RVMDUSRevolution Medicines
-23.36x63.53%$41.32B
ROIVUSRoivant Sciences
-105.78x145.04%$28.16B
INSMUSInsmed
-30.19x74.48%$26.42B
BNTXUSBioNTech SE
-12.57x19.17%$24.62B
SMMTUSSummit Therapeutics
-15.75x18.58%$13.48B
BBIOUSBridgebio Pharma
-18.81x28.57%$13.02B
MDGLUSMadrigal Pharma
-37.10x50.86%$12.06B
TWSTUSTwist Bioscience
-79.85x24.61%$10.92B
KYMRUSKymera Therapeutics
-32.66x4.94%$9.78B
ARWRUSArrowHead Pharma
-30.37x36,308.30%$9.72B
CYTKUSCytokinetics
-10.51x6.37%$9.39B
ABVXUSAbivax SA
-23.24x32.59%$9.02B
IBRXUSImmunityBio
-9.02x152.63%$8.96B
PCVXUSVaxcyte
-8.24x48.80%$8.77B
PRAXUSPraxis Precision Medicines
-24.61x3.05%$8.34B
SYREUSSpyre Therapeutics
-54.02x47.81%$8.11B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.